Overview

Full Product Details

Author:   Varghese John (Buck Institute for Age Research, CA, USA)
Publisher:   John Wiley & Sons Inc
Imprint:   John Wiley & Sons Inc
Dimensions:   Width: 16.30cm , Height: 1.90cm , Length: 24.10cm
Weight:   0.549kg
ISBN:  

9780470293423

ISBN 10:   047029342
Pages:   272
Publication Date:   19 March 2010
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   Out of stock  
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.

Table of Contents

PREFACE. ACKNOWLEDGMENTS. CONTRIBUTORS. CHAPTER 1 BACE, APP PROCESSING, AND SIGNAL TRANSDUCTION IN ALZHEIMER'S DISEASE (Dale E. Bredesen and Edward H. Koo). 1.1 Introduction. 1.2 BACE Cleavage of APP as a Molecular Switching Mechanism. 1.3 AD: An Imbalance in Cellular Dependence? 1.4 BACE Cleavage, Caspase Cleavage, and Neuronal Trophic Dependence. 1.5 BACE Cleavage of APP, Dependence Receptors, and Alzheimer Pathology. 1.6 Key Mutations Proximal of APP Processing to Aβ. 1.7 Final Remarks. CHAPTER 2 IDENTIFICATION OF BACE AS A TARGET IN ALZHEIMER'S DISEASE (Robert L. Heinrikson and Sukanto Sinha). 2.1 Introduction. 2.2 The Search for β-Secretase. 2.3 Validation of the BACE Target. 2.4 Final Remarks. CHAPTER 3 BACE BIOLOGICAL ASSAYS (Alfredo G. Tomasselli and Michael J. Bienkowski). 3.1 Introduction. 3.2 Clinical and Physiological Hallmarks of Alzheimer’s Disease (AD). 3.3 APP Processing. 3.4 Aspartyl Protease Classification. 3.5 BACE Structure. 3.6 Mechanism, Kinetics, Inhibition, and Specificity. 3.7 Assay Strategies for Inhibitor Finding and Development. 3.8 Common Assays Used to Identify and Study Inhibitors. 3.9 BACE Assays. 3.10 Final Remarks. CHAPTER 4 PEPTIDIC, PEPTIDOMIMETIC, AND HTS-DERIVED BACE INHIBITORS (James P. Beck and Dustin J. Mergott). 4.1 Introduction. 4.2 Elan/Pharmacia (Pfizer). 4.3 Oklahoma Medical Research Foundation (OMRF)/Multiple Collaborators. 4.4 Eli Lilly. 4.5 Merck. 4.6 GlaxoSmithKline. 4.7 Schering Plough. 4.8 Bristol-Myers Squibb. 4.9 Novartis. 4.10 Amgen. 4.11 Wyeth. 4.12 Final Remarks. CHAPTER 5 FRAGMENT-BASED APPROACHES FOR IDENTIFICATION OF BACE INHIBITORS (Andreas Kuglstatter and Michael Hennig). 5.1 Introduction. 5.2 Biophysical Methods Applied to BACE Fragment Screens. 5.3 BACE Inhibitors Identified by Fragment Screening. 5.4 Final Remarks. CHAPTER 6 STRUCTURE-BASED DESIGN OF BACE INHIBITORS: TECHNICAL AND PRACTICAL ASPECTS OF PREPARATION, 3-DIMENSIONAL STRUCTURE, AND COMPUTATIONAL ANALYSIS (Felix F. Vajdos, Veerabahu Shanmugasundaram, and Alfredo G. Tomasselli). 6.1 Introduction. 6.2 Preparation of BACE for Structural Studies. 6.3 Crystallographic Studies of BACE. 6.4 Structural Studies with BACE Inhibitors: Peptidomimetics and Nonpeptidomimetics. 6.5 Computational Approaches. 6.6 Final Remarks. CHAPTER 7 PHARMACOLOGICAL MODELS FOR PRECLINICAL TESTING: FROM MOUSE TO DOG TO NONHUMAN PRIMATES (Jason L. Eriksen, Michael Paul Murphy, and Elizabeth Head). 7.1 Introduction. 7.2 BACE1 and Mouse Models of AD. 7.3 Testing BACE Inhibitors in the Canine Model of Human Aging and AD. 7.4 BACE Inhibitors and Nonhuman Primates. 7.5 Final Remarks. CHAPTER 8 ADSORPTION, DISTRIBUTION, METABOLISM, EXCRETION (ADME), EFFICACY, AND TOXICOLOGY FOR BACE INHIBITORS (Ishrut Hussain and Emmanuel Demont). 8.1 Introduction. 8.2 Development of BACE Inhibitors with Optimized ADME Properties. 8.3 In Vivo Efficacy of BACE Inhibitors. 8.4 Toxicology of BACE Inhibitors. 8.5 Final Remarks. CHAPTER 9 CLINICAL TRIALS FOR DISEASE-MODIFYING DRUGS SUCH AS BACE INHIBITORS (Henry H. Hsu). 9.1 Introduction. 9.2 Update on Beta-Amyloid Therapies in Clinical Development. 9.3 Clinical Development of BACE Inhibitors and Other Disease-Modifying Drugs. 9.4 Final Remarks. CHAPTER 10 FUTURE STRATEGIES FOR DEVELOPMENT OF NOVEL BACE INHIBITORS: ANTI-APP β-SITE ANTIBODY AND APP BINDING SMALL MOLECULE APPROACHES FOR ALZHEIMER'S DISEASE (Beka Solomon, Michal Arbel-Ornath, Clare Peters-Libeu, and Varghese John). 10.1 Introduction. 10.2 β-Secretase: Discovery, Function, and Inhibitors. 10.3 Generation of Aβ Peptides via the Endocytic Pathway. 10.4 Generation of Anti-APP β-Site Antibodies. 10.5 Antibody Interference with Aβ Production in Cellular Model. 10.6 Antibody Interference with Aβ Production in Animal Models. 10.7 Identification of APP Binding Small Molecules that Block β-Site Cleavage of APP. 10.8 Final Remarks. AFTERWORD (Ruth Abraham). Introduction. Artwork as a Measure of the Progression of AD. INDEX.

Reviews

Overall this book is a timely and comprehensive resource covering developments in BACE-targeted therapeutic agents from infancy to the present time. It will prove to be valuable to researchers working in the AD field, as well as to medicinal chemists seeking to learn more about rational design of aspartyl protease inhibitors. ( ChemMedChem , November 2010)

Overall this book is a timely and comprehensive resource covering developments in BACE-targeted therapeutic agents from infancy to the present time. It will prove to be valuable to researchers working in the AD field, as well as to medicinal chemists seeking to learn more about rational design of aspartyl protease inhibitors. (ChemMedChem, November 2010)

Author Information

VARGHESE JOHN is Director of Alzheimer's Drug Discovery at the Buck Institute for Age Research. He is a chemist with many years of pharmaceutical industry experience in discovery and development of drugs for CNS diseases with a primary focus on Alzheimer's disease (AD). Dr. John has many publications and patents to his credit.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions